Kornimate/medical-research-clean huggingface dataset:
postoperative pain evaluation of novel bioceramic-based root canal sealers

Conditions: Postoperative Pain, Acute

Summary: brief summary: the purpose of this study was to evaluate the effect of mta-bioseal, guttaflow bioseal, and neosealer flo calcium-silicate based root canal sealers on postobturation pain in teeth with asymptomatic irreversible pulpitis or chronic apical periodontitis undergoing single-visit root canal treatment. the study tried to answer whether the type of sealer used altered the incidence and intensity of postobturation endodontic pain, whether pulp status affected the incidence and intensity of postobturation endodontic pain and whether there was no difference in analgesic intake by patients after a single-visit root canal treatment between the experimental groups.

this prospective clinical study was reported pain levels experienced after obturation were similar for the different pulp statuses and root canal sealers tested. the participants with single-rooted teeth were included and divided into four groups according to the root canal sealer used. then, the patients were divided into two subgroups according to pulp vitality. the postobturation pain scores were recorded after obturation on a visual analog scale (vas) at 6, 12, 24, and 48 hours, and at 7 and 30 days. the level of pain experienced after obturation was similar for all root canal sealers in different pulp statuses. the results of the study showed that the bioceramic-based sealers tested can be used safely in clinical practice in terms of postobturation pain.

Eligibility criteria:
inclusion criteria: * good oral hygiene, * not reporting pain before the appointment * asymptomatic irreversible pulpitis caused by deep carious lesions (vital cases), * asymptomatic primary apical periodontitis (non-vital cases). exclusion criteria: * pregnancy, * autoimmune diseases, * uncontrolled diabetes, * smokers, * advanced periodontal disease (with 5 mm or more probing depth), * patients requiring endodontic treatment for more than one tooth, * unrestorable coronal destruction, * incomplete root formation, systemic, * allergic sensitivity to local anesthetic or nsaids. * asa ii patient * an analgesic or antibiotic intake the 7 days before the beginning of treatment

Keywords: calcium-silicate, pain postobturation root canal sealer visual analog scale
effect of verapamil tablets on the pharmacokinetic of hrs-1893 tablets in healthy subjects

Conditions: Obstructive Hypertrophic Cardiomyopathy

Summary: the purpose of this phase ⅰ study is to evaluate the effect of oral verapamil tablets on the pharmacokinetics of hrs-1893 in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written informed consent form (icf). 2. male or female aged 18-55（adult healthy volunteers). 3. body mass index (bmi) between 19 and 28 kg/m2. 4. normal electrocardiogram (ecg). exclusion criteria: 1. history of persistent tachyarrhythmia and syncope. 2. a history of stomach or bowel surgery or excision. 3. positive results of hepatitis b surface antigen, hepatitis c antibody, syphilis antibody and human immunodeficiency virus antibody. 4. those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration.
epinephrine sprayed on the papilla for the prevention of post-ercp pancreatitis

Conditions: Post-ERCP Acute Pancreatitis

Summary: post-endoscopic retrograde cholangiopancreatography (ercp) pancreatitis (pep) has been a well-recognized complication with significant morbidity and even mortality. a variety of possible mechanisms has been suggested in the occurrence of pancreatitis, but papillary edema caused by manipulations during cannulation or endoscopic treatment has received the most attention. the papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. topical application of epinephrine on the papilla may reduce papillary edema. moreover, it is reported that epinephrine sprayed on the papilla may be effective to prevent pep. however, it is still unclear that epinephrine sprayed on the papilla can prevent acute pancreatitis after endoscopic retrograde cholangiopancreatography. we therefore designed a prospective randomized trial to determine whether epinephrine sprayed on the papilla prevent pep after ercp.

between july 2016 and december 2017, 670 consecutive patients older than 18 years who are scheduled to undergo diagnostic or therapeutic ercp at the anhui provincial hospital will be recruited for the study. patients were randomized using opaque, sealed envelopes containing random numbers assigning them to undergo a spray of epinephrine (epinephrine group) or saline (control group) on the major papilla. a two proportion equality test will be conducted to explore whether incidence rates are different. descriptive statistics including number (n), mean, median, standard deviation, minimum and maximum, will be produced for all continuous variables. frequency tables of number (n) and percentage of subjects will be produced for all categorical variables.

Eligibility criteria:
inclusion criteria: 1. males and females, age \> 18 years. 2. normal amylase level before undergoing ercp. 3. signed inform consent form and agreed to follow-up on time. exclusion criteria: 1. pregnancy or history of allergy to epinephrine. 2. medical or psychological condition that would not permit the patient to complete the study or sign the informed consent. 3. patients involved in other study within 60 days. 4. billroth ii or roux-en-y anatomy 5. acute pancreatitis. 6. all contraindications to epinephrine.
characteristics of mast cells in mastocytosis

Conditions: Mastocytosis

Summary: this study will determine what growth factors are involved in promoting and inhibiting mastocytosis-an abnormal increase of mast cells in one or more organ systems. mast cells release chemicals that can cause itching, blisters, flushing, bone pain, and abdominal pain. little is known about the disease and there is no cure. steroids and antihistamines can help reduce some symptoms. patients from birth to 80 years of age with increased mast cells in at least one organ system may be eligible for this 3-year study. family members may also be enrolled for genetic testing. patients will be evaluated yearly at the nih clinical center with the following tests and procedures: * medical history and physical examination. * blood samples. * laboratory blood tests, as medically indicated. * bone marrow aspiration and biopsy - for the bone marrow aspiration and biopsy, the back hipbone is punctured with a sterile needle. five milliliters (1 teaspoon) of marrow is withdrawn through a syringe and a 1/2-inch piece of tissue is extracted with a special needle. the blood and bone marrow samples will be used for clinical care and for research to determine if mastocytosis is due to mast cell growth factors or genetic changes. patients who require further evaluation and tests will have recommendations made to their primary physician. any patient who requires immediate treatment will be admitted to the hospital. standard medical treatment may include antihistamines for itching; steroids for severe abdominal symptoms such as cramping, diarrhea, and evidence of increased mast cells determined by an upper gi study; and adrenaline for anaphylactic shock. patients who do not respond to conventional treatment may be offered participation in an experimental therapy study. participating family members will have a medical history and a blood sample drawn to look for genetic abnormalities.

this protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving therapy. patients entered into the study are seen initially and may elect to be reevaluated yearly. the majority of patients to be entered into this protocol are currently followed at nih on other protocols. medical workup and treatment are in accordance with standard medical practice. the protocol is for 3 years, to be extended as facilities, faculty, and patients permit.

Eligibility criteria:
subjects include children and adults from birth to 80 years of age. participants must have histologic evidence of an increased mast cell number in at least one organ system. must be willing to be seen at the nih according to protocol guidelines. routine medical care must be available through their referral physician. patients with mastocytosis now followed at the nih on protocol 88-i-0190 will be continued on this study.

Keywords: il-3 stem cell factor cytokines cell differentiation receptors bone marrow mastocytosis
a pilot study evaluating a multidisciplinary chronic pain group therapy in a primary care setting

Conditions: Chronic Pain

Summary: the investigators will evaluate the effectiveness of "living everyday above-and-beyond pain" (leap) program in the primary care setting. leap is a multidisciplinary chronic pain group therapy developed for the two clinic sites of mcmaster family health team: mcmaster family practice and stonechurch family health centre. leap aims to improve patients'quality of life, interaction with the health care system and their health care utilization. this is a pilot study to evaluate mainly feasibility. the investigators will make use of both experimental and qualitative methods gather evidence of the programs success, strengths and weaknesses.


Eligibility criteria:
inclusion criteria: * 18 years and older * diagnosed with chronic pain exclusion criteria: * chronic pain related to cancer, pelvic pain or headache * inability to speak or write in english * patient is unable to attend and participate in group treatment sessions on their own * substance use or mental health problems of a severity making group treatment participation impossible * currently participating in another cognitive-behavioral pain management program * patient is receiving palliative care or has been diagnosed with an illness expecting to cause death within one year

Keywords: chronic pain primary care multidisciplinary group therapy embedded mixed-methods study
epirubicin or not in patients with top2a (topoisomerase (dna) ii alpha (170kd)) normal early breast cancer

Conditions: Breast Neoplasms

Summary: the danish breast cancer cooperative group (dbcg) wishes to clarify if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin and cyclophosphamide followed by docetaxel in patients with top2a normal and operable breast cancer.

in dbcg trial 89d we in more than 1,200 patients showed that substitution in cmf chemotherapy of methotrexate with epirubicin improves survival for patients with primary and operable breast cancer. in a retrospective evaluation we have also shown that approximately 20% of all patients in 89d have tumors with numerical changes of the top2a gene, and that only patients with abnormal top2a benefit from epirubicin. in the current trial the dbcg wishes to clarify if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin and cyclophosphamide followed by docetaxel in patients with top2a normal and operable breast cancer.

Eligibility criteria:
trial population: 1. younger than 35, but at least 18 years of age 2. hormone receptor-negative tumor (er- and pgr-negative) and 35 to 75 years of age. 3. hormone receptor-positive tumor, 35 to 59 years of age and presenting at least one of the following characteristics: spread to lymph nodes, tumor \> 2 cm, degree of malignancy ii-iii or her2-positive. inclusion criteria: 1. signed informed consent 2. histologically confirmed invasive breast carcinoma which has been micro-radical removed by breast preserving surgery or mastectomy according to dbcg's guideline 3. top2a normal tumor (score of 0.8 - 2.0) exclusion criteria: 1. pregnancy or breast-feeding 2. earlier medical cancer treatment, including docetaxel, epirubicin or cyclophosphamide. 3. distant metastases or bilateral breast cancer (excluded after checking by means of chest radiography, bilateral mammography and normal blood samples as a minimum). 4. other active, malign disease in the latest 5 years, except for adequately treated and cured carcinoma in situ cervices uteri or non-melanoma skin cancer. 5. comorbidity score \> 3 (patients with a score of 1-2 start at dose level -1). 6. treatment with a non-approved product or test product in the latest 30 days. 7. known severe hypersensitivity to docetaxel, epirubicin or cyclophosphamide or auxiliary agents in these products.

Keywords: epirubicin docetaxel adjuvant chemotherapy dna topoisomerases, type ii
predicting post extubation stridor after maxillomandibular fixation

Conditions: Stridor; Larynx Edema

Summary: endotracheal intubation can induce laryngotracheal injury which results in narrowing of the airway due to edema of the glottis. this can increase the risk of development of post-extubation stridor (pes)

ultrasound (us) is a useful and non-invasive tool for the evaluation of vocal cords and laryngeal morphology in intubated patients. the laryngeal air-column width (lacw), laryngeal air column width difference (lacwd), and laryngeal air-column width ratio (lacwr) measured by ultrasound can potentially identify patients at risk of post-extubation stridor, in whom caution should be taken after extubation. the cuff-leak test can predict successful extubation through using the difference between the expired tidal volume with the cuff inflated and with the cuff deflated; the higher the leak, the lower the likelihood that post-extubation stridor will occur.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years) * american society of anesthesiologists status i and ii * undergoing elective maxillomandibular fixation surgeries under general anesthesia with nasal endotracheal intubation exclusion criteria: * patients' refusal * pregnant females * patients with body mass index \<18.5 or ≥ 35 kg/m2 * risk of aspiration * cardiorespiratory disorder * neuromuscular disease * uncontrolled diabetes mellitus * gastrointestinal bleeding * on chronic steroid therapy * intubated patients or were intubated or had upper airway infection within 1 week prior to surgery * history of any pathology, radiotherapy or surgery in the neck * had difficult laryngeal us plane (as neck wound)
pattern laser versus conventional laser in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: purpose: to evaluate the clinical efficiency, safety and painfulness of retinal laser photocoagulation employing a pattern scanning laser system pascal given in a single-session versus conventional laser multiple-session treatment of the same patient with diabetic retinopathy. methods: the cohort included 60 eyes in 30 patients treated at the ophthalmology clinic, faculty hospital ostrava, from 2008 to 2013. panretinal laser coagulation was performed on one eye using the multispot panretinal photocoagulation given in a single-session system pascal (ssp) (optimedica, santa clara, california). on the other eye laser treatment was carried out by the classic conventional multiple-session method (msm).


Eligibility criteria:
inclusion criteria: * diabetic retinopathy exclusion criteria: * no

Keywords: diabetic retinopathy patterns low time of impulse pascal
treatment of upper extremity deep-vein thrombosis

Conditions: Deep-Vein Thrombosis

Summary: the purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with fragmin (dalteparin sodium injection) for three months.

upper extremity deep-vein thrombosis (dvt) is an increasingly common clinical problem and has been found to cause important pulmonary embolism in up to 36% of cases including fatal embolism. the major risk factor for development of dvt is presence of a central venous catheter in which up to 30% of patients may develop venous thrombosis. peripherally inserted central catheters or (picc) lines have been more frequently used in order to avoid the morbidity of central venous catheter insertion. there is little data on the incidence of dvt with these catheters, or effective treatment regimen. the purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with fragmin (dalteparin sodium injection) for three months. about 100 patients will be enrolled in this study at the university of oklahoma. all patients with upper extremity dvt will be screened. each will have a complete baseline and risk factor assessment. all patients will receive active study drug for a period of 3 months with reassessment of upper extremity dvt by ultrasound. all patients will participate for a period of 12 months with follow up visits at 5-7 day, and 1, 3, 6, 12 months.

Eligibility criteria:
inclusion criteria: * patients with confirmed upper extremity dvt diagnosed by ultrasound imaging or venogram exclusion criteria: * active, clinically significant bleeding * known hypersensitivity to heparin or low-molecular weight heparin * currently pregnant or less than 1 week post-partum * acquired bleeding diathesis * known inherited bleeding disorder * renal failure * extremes of weight * poor performance status * unable to return for repeat diagnostic testing or follow-up visits

Keywords: upper extremity deep-vein thrombosis dvt fragmin deep-vein thrombosis thrombosis
timing of tracheotomy in covid-19 patients

Conditions: Covid-19; ARDS; Tracheostomy Complication; Respiratory Insufficiency; Corona Virus Infection

Summary: critically ill covid-19 patients may require respiratory support including mechanical ventilation. after an initial period with an endotracheal tube, a tracheotomy is performed in order to reduce potential airway complications, reduce the need of sedation and facilitate the monitoring and recovery. the optimal timing of this surgical procedure is, however, still unknown. the aim of this randomized, controlled trial is to compare the outcome of early (within 7 days after intubation) vs late (at least 10 days after intubation) tracheotomy in covid-19 patients. the need for mechanical ventilation, sedation, additional oxygen support, frequency of complications, duration at the icu and mortality through the icu stay will be evaluated and compared.


Eligibility criteria:
inclusion criteria: * verified covid-19 infection * intubated due to respiratory insufficiency and need for mechanical ventilation * informed consent from patient or relative exclusion criteria: * age below 18 years * need for mechanical ventilation less than 14 days * tracheotomy not possible within 7 days * tracheotomy not possible due to anatomical or other medical reasons

Keywords: covid-19 tracheotomy tracheostomy rct ards
efficacy and safety of dalbavancin compared to standard of care antibiotic therapy for the completion of treatment of patients with complicated bacteremia or infective endocarditis

Conditions: Endocarditis; Bacteremia

Summary: this study will compare dalbavancin to standard of care (soc) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.


Eligibility criteria:
inclusion criteria: * a diagnosis of complicated bacteremia or infective endocarditis * gram-positive bacteremia at screening with methicillin-susceptible staphylococcus aureus (mssa), methicillin-resistant staphylococcus aureus (mrsa) or streptococci * treatment with standard of care antibiotics for 72 hours (h) - 10 days * defervescence for at least 24h and clearance of bacteremia from screening pathogen. exclusion criteria: * embolic events * history of prosthetic valve surgery, cardiac device or prosthetic joint * left-sided endocarditis due to staphylococcus aureus (s. aureus) * large mobile vegetations (\>10 mm) on mitral valves * perivalvular abscess * uncomplicated bacteremia due to s. aureus * gram-negative bacteria or fungi in blood cultures * heart failure associated with infective endocarditis \[left ventricular ejection fraction (lvef) \<40%\] * intravascular material or removable infection source not intended to be removed within 4 days postrandomization * planned valve replacement surgery within 3 days of randomization * refractory shock, significant hepatic insufficiency or severe leukopenia \[absolute neutrophil count (anc) \< 500 cells/mm\^3\] * known osteomyelitis * hypersensitivity to dalbavancin or other drugs in glycopeptide class * infection with enterococci, coagulase-negative staphylococci, or with organism not susceptible to dalbavancin or vancomycin * immunosuppression/immune deficiency * concomitant systemic antibacterial therapy for gram-positive infection other than that allowed in protocol * pregnant or nursing females.
reliability and validity of the turkish version of the pedsql 3.0 neuromuscular module for 2-to 4- year-old

Conditions: Spinal Muscular Atrophy; Quality of Life; Neuromuscular Diseases; Pediatric Disorder

Summary: the aim of the investigator's study was to investigate translating the pedsql 3.0 neuromuscular module for 2-to 4- year-old and using it in clinics reliably and validity with a turkish version of the pedsql generic core (pediatric quality of life questionnare) in children with spinal muscular atrophy in turkey

the pedsql 3.0 neuromuscular module for 2-to 4- year-old will be translated into turkish by following the language translation steps. first of all, the english form will be translated into turkish by two people who are fluent in english. then, the forms translated by another expert in the field will be reviewed. the revised text will be translated from turkish into english by another person with a good command of english and will be compared with the original scale by the lecturer. if a significant change in meaning is not detected, the scale will be applied to 10 parents. in case of incomprehensible questions, which are reported to be lacking in expression, the scale will be finalized after revision and corrections are made by the research team.

Eligibility criteria:
inclusion criteria: * having a child with spinal muscular atrophy * having a child between the ages of 2-4 * accept to participate in the study exclusion criteria: * lack of cooperation during work * presence of disease other than sma, which will prevent participation in the study

Keywords: spinal muscular atrophy quality of life neuromuscular diseases